5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Hypertension O
including O
hypertensive O
crisis O
has O
been O
observed O
. O

Blood O
pressure O
should O
be O
well-controlled O
prior O
to O
initiating O
INLYTA O
. O

Monitor O
for O
hypertension O
and O
treat O
as O
needed O
. O

For O
persistent O
hypertension O
despite O
use O
of O
anti-hypertensive O
medications O
, O
reduce O
the O
INLYTA O
dose O
. O

( O
5.1 O
) O
* O
Arterial O
and O
venous O
thrombotic O
events O
have O
been O
observed O
and O
can O
be O
fatal O
. O

Use O
with O
caution O
in O
patients O
who O
are O
at O
increased O
risk O
for O
these O
events O
. O

( O
5.2 O
, O
5.3 O
) O
* O
Hemorrhagic O
events O
, O
including O
fatal O
events O
, O
have O
been O
reported O
. O

INLYTA O
has O
not O
been O
studied O
in O
patients O
with O
evidence O
of O
untreated O
brain O
metastasis O
or O
recent O
active O
gastrointestinal O
bleeding O
and O
should O
not O
be O
used O
in O
those O
patients O
. O

( O
5.4 O
) O
* O
Cardiac O
failure O
has O
been O
observed O
and O
can O
be O
fatal O
. O

Monitor O
for O
signs O
or O
symptoms O
of O
cardiac O
failure O
throughout O
treatment O
with O
INLYTA O
. O

( O
5.5 O
) O
* O
Gastrointestinal O
perforation O
and O
fistula O
, O
including O
death O
, O
have O
occurred O
. O

Use O
with O
caution O
in O
patients O
at O
risk O
for O
gastrointestinal O
perforation O
or O
fistula O
. O

( O
5.6 O
) O
* O
Hypothyroidism O
requiring O
thyroid O
hormone O
replacement O
has O
been O
reported O
. O

Monitor O
thyroid O
function O
before O
initiation O
of O
, O
and O
periodically O
throughout O
, O
treatment O
with O
INLYTA O
. O

( O
5.7 O
) O
* O
Stop O
INLYTA O
at O
least O
24 O
hours O
prior O
to O
scheduled O
surgery O
. O

( O
5.8 O
) O
* O
Reversible O
Posterior O
Leukoencephalopathy O
Syndrome O
( O
RPLS O
) O
has O
been O
observed O
. O

Permanently O
discontinue O
INLYTA O
if O
signs O
or O
symptoms O
of O
RPLS O
occur O
. O

( O
5.9 O
) O
* O
Monitor O
for O
proteinuria O
before O
initiation O
of O
, O
and O
periodically O
throughout O
, O
treatment O
with O
INLYTA O
. O

For O
moderate O
to O
severe O
proteinuria O
, O
reduce O
the O
dose O
or O
temporarily O
interrupt O
treatment O
with O
INLYTA O
. O

( O
5.10 O
) O
* O
Liver O
enzyme O
elevation O
has O
been O
observed O
during O
treatment O
with O
INLYTA O
. O

Monitor O
ALT O
, O
AST O
and O
bilirubin O
before O
initiation O
of O
, O
and O
periodically O
throughout O
, O
treatment O
with O
INLYTA O
. O

( O
5.11 O
) O
* O
The O
starting O
dose O
of O
INLYTA O
should O
be O
decreased O
if O
used O
in O
patients O
with O
moderate O
hepatic O
impairment O
. O

INLYTA O
has O
not O
been O
studied O
in O
patients O
with O
severe O
hepatic O
impairment O
. O

( O
2.2 O
, O
5.12 O
) O
* O
INLYTA O
can O
cause O
fetal O
harm O
when O
administered O
to O
a O
pregnant O
woman O
based O
on O
its O
mechanism O
of O
action O
. O

Women O
of O
childbearing O
potential O
should O
be O
advised O
of O
the O
potential O
hazard O
to O
the O
fetus O
and O
to O
avoid O
becoming O
pregnant O
while O
receiving O
INLYTA O
. O

( O
5.13 O
, O
8.1 O
) O
5.1 O
Hypertension O
and O
Hypertensive O
Crisis O
In O
a O
controlled O
clinical O
study O
with O
INLYTA O
for O
the O
treatment O
of O
patients O
with O
RCC B-Not_AE_Candidate
, O
hypertension B-OSE_Labeled_AE
was O
reported O
in O
145/359 O
patients O
( O
40 O
% O
) O
receiving O
INLYTA O
and O
103/355 O
patients O
( O
29 O
% O
) O
receiving O
sorafenib O
. O

Grade O
3/4 O
hypertension B-OSE_Labeled_AE
was O
observed O
in O
56/359 O
patients O
( O
16 O
% O
) O
receiving O
INLYTA O
and O
39/355 O
patients O
( O
11 O
% O
) O
receiving O
sorafenib O
. O

Hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
was O
reported O
in O
2/359 O
patients O
( O
< O
1 O
% O
) O
receiving O
INLYTA O
and O
none O
of O
the O
patients O
receiving O
sorafenib O
. O

The O
median O
onset O
time O
for O
hypertension B-OSE_Labeled_AE
( O
systolic B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
> I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mmHg I-OSE_Labeled_AE
or O
diastolic B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
> I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mmHg I-OSE_Labeled_AE
) O
was O
within O
the O
first O
month O
of O
the O
start O
of O
INLYTA O
treatment O
and O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
increases I-OSE_Labeled_AE
have O
been O
observed O
as O
early O
as O
4 O
days O
after O
starting O
INLYTA O
. O

Hypertension B-NonOSE_AE
was O
managed O
with O
standard O
antihypertensive O
therapy O
. O

Discontinuation O
of O
INLYTA O
treatment O
due O
to O
hypertension B-OSE_Labeled_AE
occurred O
in O
1/359 O
patients O
( O
< O
1 O
% O
) O
receiving O
INLYTA O
and O
none O
of O
the O
patients O
receiving O
sorafenib O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Blood O
pressure O
should O
be O
well-controlled O
prior O
to O
initiating O
INLYTA O
. O

Patients O
should O
be O
monitored O
for O
hypertension B-NonOSE_AE
and O
treated O
as O
needed O
with O
standard O
anti B-NonOSE_AE
- I-NonOSE_AE
hypertensive I-NonOSE_AE
therapy I-NonOSE_AE
. O

In O
the O
case O
of O
persistent O
hypertension B-NonOSE_AE
despite O
use O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
hypertensive I-NonOSE_AE
medications I-NonOSE_AE
, O
reduce O
the O
INLYTA O
dose O
. O

Discontinue O
INLYTA O
if O
hypertension B-NonOSE_AE
is O
severe O
and O
persistent O
despite O
anti B-NonOSE_AE
- I-NonOSE_AE
hypertensive I-NonOSE_AE
therapy I-NonOSE_AE
and O
dose O
reduction O
of O
INLYTA O
, O
and O
discontinuation O
should O
be O
considered O
if O
there O
is O
evidence O
of O
hypertensive B-NonOSE_AE
crisis I-NonOSE_AE
. O

If O
INLYTA O
is O
interrupted O
, O
patients O
receiving O
antihypertensive O
medications O
should O
be O
monitored O
for O
hypotension B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.2 O
Arterial O
Thromboembolic O
Events O
In O
clinical O
trials O
, O
arterial B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
have O
been O
reported O
, O
including O
deaths B-NonOSE_AE
. O

In O
a O
controlled O
clinical O
study O
with O
INLYTA O
for O
the O
treatment O
of O
patients O
with O
RCC B-Not_AE_Candidate
, O
Grade O
3/4 O
arterial B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
reported O
in O
4/359 O
patients O
( O
1 O
% O
) O
receiving O
INLYTA O
and O
4/355 O
patients O
( O
1 O
% O
) O
receiving O
sorafenib O
. O

Fatal B-NonOSE_AE
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
was O
reported O
in O
1/359 O
patients O
( O
< O
1 O
% O
) O
receiving O
INLYTA O
and O
none O
of O
the O
patients O
receiving O
sorafenib O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

In O
clinical O
trials O
with O
INLYTA O
, O
arterial B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
( O
including O
transient B-OSE_Labeled_AE
ischemic I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
and O
retinal B-OSE_Labeled_AE
artery I-OSE_Labeled_AE
occlusion I-OSE_Labeled_AE
) O
were O
reported O
in O
17/715 O
patients O
( O
2 O
% O
) O
, O
with O
two O
deaths B-NonOSE_AE
secondary O
to O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
. O

Use O
INLYTA O
with O
caution O
in O
patients O
who O
are O
at O
risk O
for O
, O
or O
who O
have O
a O
history O
of O
, O
these O
events O
. O

INLYTA O
has O
not O
been O
studied O
in O
patients O
who O
had O
an O
arterial B-Not_AE_Candidate
thromboembolic I-Not_AE_Candidate
event I-Not_AE_Candidate
within O
the O
previous O
12 O
months O
. O

5.3 O
Venous O
Thromboembolic O
Events O
In O
clinical O
trials O
, O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
have O
been O
reported O
, O
including O
deaths B-NonOSE_AE
. O

In O
a O
controlled O
clinical O
study O
with O
INLYTA O
for O
the O
treatment O
of O
patients O
with O
RCC B-Not_AE_Candidate
, O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
reported O
in O
11/359 O
patients O
( O
3 O
% O
) O
receiving O
INLYTA O
and O
2/355 O
patients O
( O
1 O
% O
) O
receiving O
sorafenib O
. O

Grade O
3/4 O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
reported O
in O
9/359 O
patients O
( O
3 O
% O
) O
receiving O
INLYTA O
( O
including O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
retinal B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
occlusion I-OSE_Labeled_AE
and O
retinal B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
) O
and O
2/355 O
patients O
( O
1 O
% O
) O
receiving O
sorafenib O
. O

Fatal B-NonOSE_AE
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
was O
reported O
in O
1/359 O
patients O
( O
< O
1 O
% O
) O
receiving O
INLYTA O
and O
none O
of O
the O
patients O
receiving O
sorafenib O
. O

In O
clinical O
trials O
with O
INLYTA O
, O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
reported O
in O
22/715 O
patients O
( O
3 O
% O
) O
, O
with O
two O
deaths B-NonOSE_AE
secondary O
to O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
. O

Use O
INLYTA O
with O
caution O
in O
patients O
who O
are O
at O
risk O
for O
, O
or O
who O
have O
a O
history O
of O
, O
these O
events O
. O

INLYTA O
has O
not O
been O
studied O
in O
patients O
who O
had O
a O
venous B-Not_AE_Candidate
thromboembolic I-Not_AE_Candidate
event I-Not_AE_Candidate
within O
the O
previous O
6 O
months O
. O

5.4 O
Hemorrhage O
In O
a O
controlled O
clinical O
study O
with O
INLYTA O
for O
the O
treatment O
of O
patients O
with O
RCC B-Not_AE_Candidate
, O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
reported O
in O
58/359 O
patients O
( O
16 O
% O
) O
receiving O
INLYTA O
and O
64/355 O
patients O
( O
18 O
% O
) O
receiving O
sorafenib O
. O

Grade O
3/4 O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
reported O
in O
5/359 O
( O
1 O
% O
) O
patients O
receiving O
INLYTA O
( O
including O
cerebral B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
hemoptysis B-OSE_Labeled_AE
, O
lower B-OSE_Labeled_AE
gastrointestinal I-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
and O
melena B-OSE_Labeled_AE
) O
and O
11/355 O
( O
3 O
% O
) O
patients O
receiving O
sorafenib O
. O

Fatal B-NonOSE_AE
hemorrhage B-OSE_Labeled_AE
was O
reported O
in O
1/359 O
patients O
( O
< O
1 O
% O
) O
receiving O
INLYTA O
( O
gastric B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
) O
and O
3/355 O
patients O
( O
1 O
% O
) O
receiving O
sorafenib O
. O

INLYTA O
has O
not O
been O
studied O
in O
patients O
who O
have O
evidence O
of O
untreated O
brain B-Not_AE_Candidate
metastasis I-Not_AE_Candidate
or O
recent O
active B-Not_AE_Candidate
gastrointestinal I-Not_AE_Candidate
bleeding I-Not_AE_Candidate
and O
should O
not O
be O
used O
in O
those O
patients O
. O

If O
any O
bleeding B-NonOSE_AE
requires O
medical O
intervention O
, O
temporarily O
interrupt O
the O
INLYTA O
dose O
. O

5.5 O
Cardiac O
Failure O
In O
a O
controlled O
clinical O
study O
with O
INLYTA O
for O
the O
treatment O
of O
patients O
with O
RCC B-Not_AE_Candidate
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
was O
reported O
in O
6/359 O
patients O
( O
2 O
% O
) O
receiving O
INLYTA O
and O
3/355 O
patients O
( O
1 O
% O
) O
receiving O
sorafenib O
. O

Grade O
3/4 O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
was O
observed O
in O
2/359 O
patients O
( O
1 O
% O
) O
receiving O
INLYTA O
and O
1/355 O
patients O
( O
< O
1 O
% O
) O
receiving O
sorafenib O
. O

Fatal B-NonOSE_AE
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
was O
reported O
in O
2/359 O
patients O
( O
1 O
% O
) O
receiving O
INLYTA O
and O
1/355 O
patients O
( O
< O
1 O
% O
) O
receiving O
sorafenib O
. O

Monitor O
for O
signs O
or O
symptoms O
of O
cardiac B-NonOSE_AE
failure I-NonOSE_AE
throughout O
treatment O
with O
INLYTA O
. O

Management O
of O
cardiac B-NonOSE_AE
failure I-NonOSE_AE
may O
require O
permanent O
discontinuation O
of O
INLYTA O
. O

5.6 O
Gastrointestinal O
Perforation O
and O
Fistula O
Formation O
In O
a O
controlled O
clinical O
study O
with O
INLYTA O
for O
the O
treatment O
of O
patients O
with O
RCC O
, O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
was O
reported O
in O
1/359 O
patients O
( O
< O
1 O
% O
) O
receiving O
INLYTA O
and O
none O
of O
the O
patients O
receiving O
sorafenib O
. O

In O
clinical O
trials O
with O
INLYTA O
, O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
was O
reported O
in O
5/715 O
patients O
( O
1 O
% O
) O
, O
including O
one O
death B-NonOSE_AE
. O

In O
addition O
to O
cases O
of O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
, O
fistulas O
were O
reported O
in O
4/715 O
patients O
( O
1 O
% O
) O
. O

Monitor O
for O
symptoms O
of O
gastrointestinal B-NonOSE_AE
perforation I-NonOSE_AE
or O
fistula O
periodically O
throughout O
treatment O
with O
INLYTA O
. O

5.7 O
Thyroid O
Dysfunction O
In O
a O
controlled O
clinical O
study O
with O
INLYTA O
for O
the O
treatment O
of O
patients O
with O
RCC B-Not_AE_Candidate
, O
hypothyroidism B-OSE_Labeled_AE
was O
reported O
in O
69/359 O
patients O
( O
19 O
% O
) O
receiving O
INLYTA O
and O
29/355 O
patients O
( O
8 O
% O
) O
receiving O
sorafenib O
. O

Hyperthyroidism B-OSE_Labeled_AE
was O
reported O
in O
4/359 O
patients O
( O
1 O
% O
) O
receiving O
INLYTA O
and O
4/355 O
patients O
( O
1 O
% O
) O
receiving O
sorafenib O
. O

In O
patients O
who O
had O
thyroid B-Not_AE_Candidate
stimulating I-Not_AE_Candidate
hormone I-Not_AE_Candidate
( I-Not_AE_Candidate
TSH I-Not_AE_Candidate
) I-Not_AE_Candidate
< I-Not_AE_Candidate
5 I-Not_AE_Candidate
muU I-Not_AE_Candidate
/ I-Not_AE_Candidate
mL I-Not_AE_Candidate
before O
treatment O
, O
elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
TSH I-OSE_Labeled_AE
to O
> O
=10 O
muU/mL O
occurred O
in O
79/245 O
patients O
( O
32 O
% O
) O
receiving O
INLYTA O
and O
25/232 O
patients O
( O
11 O
% O
) O
receiving O
sorafenib O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Monitor O
thyroid O
function O
before O
initiation O
of O
, O
and O
periodically O
throughout O
, O
treatment O
with O
INLYTA O
. O

Treat O
hypothyroidism B-NonOSE_AE
and O
hyperthyroidism B-NonOSE_AE
according O
to O
standard O
medical O
practice O
to O
maintain O
euthyroid O
state O
. O

5.8 O
Wound O
Healing O
Complications O
No O
formal O
studies O
of O
the O
effect O
of O
INLYTA O
on O
wound B-Not_AE_Candidate
healing I-Not_AE_Candidate
have O
been O
conducted O
. O

Stop O
treatment O
with O
INLYTA O
at O
least O
24 O
hours O
prior O
to O
scheduled O
surgery O
. O

The O
decision O
to O
resume O
INLYTA O
therapy O
after O
surgery O
should O
be O
based O
on O
clinical O
judgment O
of O
adequate O
wound O
healing O
. O

5.9 O
Reversible O
Posterior O
Leukoencephalopathy O
Syndrome O
In O
a O
controlled O
clinical O
study O
with O
INLYTA O
for O
the O
treatment O
of O
patients O
with O
RCC B-Not_AE_Candidate
, O
reversible B-OSE_Labeled_AE
posterior I-OSE_Labeled_AE
leukoencephalopathy I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
RPLS I-OSE_Labeled_AE
) O
was O
reported O
in O
1/359 O
patients O
( O
< O
1 O
% O
) O
receiving O
INLYTA O
and O
none O
of O
the O
patients O
receiving O
sorafenib O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

There O
were O
two O
additional O
reports O
of O
RPLS B-OSE_Labeled_AE
in O
other O
clinical O
trials O
with O
INLYTA O
. O

RPLS B-NonOSE_AE
is O
a O
neurological O
disorder O
which O
can O
present O
with O
headache B-NonOSE_AE
, O
seizure B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
blindness B-NonOSE_AE
and O
other O
visual B-NonOSE_AE
and O
neurologic O
disturbances I-NonOSE_AE
. O

Mild O
to O
severe O
hypertension B-NonOSE_AE
may O
be O
present O
. O

Magnetic O
resonance O
imaging O
is O
necessary O
to O
confirm O
the O
diagnosis O
of O
RPLS B-NonOSE_AE
. O

Discontinue O
INLYTA O
in O
patients O
developing O
RPLS B-NonOSE_AE
. O

The O
safety O
of O
reinitiating O
INLYTA O
therapy O
in O
patients O
previously O
experiencing O
RPLS B-Not_AE_Candidate
is O
not O
known O
. O

5.10 O
Proteinuria O
In O
a O
controlled O
clinical O
study O
with O
INLYTA O
for O
the O
treatment O
of O
patients O
with O
RCC B-Not_AE_Candidate
, O
proteinuria B-OSE_Labeled_AE
was O
reported O
in O
39/359 O
patients O
( O
11 O
% O
) O
receiving O
INLYTA O
and O
26/355 O
patients O
( O
7 O
% O
) O
receiving O
sorafenib O
. O

Grade O
3 O
proteinuria B-OSE_Labeled_AE
was O
reported O
in O
11/359 O
patients O
( O
3 O
% O
) O
receiving O
INLYTA O
and O
6/355 O
patients O
( O
2 O
% O
) O
receiving O
sorafenib O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Monitoring O
for O
proteinuria B-NonOSE_AE
before O
initiation O
of O
, O
and O
periodically O
throughout O
, O
treatment O
with O
INLYTA O
is O
recommended O
. O

For O
patients O
who O
develop O
moderate O
to O
severe O
proteinuria B-NonOSE_AE
, O
reduce O
the O
dose O
or O
temporarily O
interrupt O
INLYTA O
treatment O
. O

5.11 O
Elevation O
of O
Liver O
Enzymes O
In O
a O
controlled O
clinical O
study O
with O
INLYTA O
for O
the O
treatment O
of O
patients O
with O
RCC B-Not_AE_Candidate
, O
alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
) I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
of O
all O
grades O
occurred O
in O
22 O
% O
of O
patients O
on O
both O
arms O
, O
with O
Grade O
3/4 O
events O
in O
< O
1 O
% O
of O
patients O
on O
the O
INLYTA O
arm O
and O
2 O
% O
of O
patients O
on O
the O
sorafenib O
arm O
. O

Monitor O
ALT O
, O
aspartate O
aminotransferase O
( O
AST O
) O
and O
bilirubin O
before O
initiation O
of O
and O
periodically O
throughout O
treatment O
with O
INLYTA O
. O

5.12 O
Hepatic O
Impairment O
The O
systemic O
exposure O
to O
axitinib O
was O
higher O
in O
subjects O
with O
moderate O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
( O
Child B-Not_AE_Candidate
- I-Not_AE_Candidate
Pugh I-Not_AE_Candidate
class I-Not_AE_Candidate
B I-Not_AE_Candidate
) O
compared O
to O
subjects O
with O
normal O
hepatic O
function O
. O

A O
dose O
decrease O
is O
recommended O
when O
administering O
INLYTA O
to O
patients O
with O
moderate O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
( O
Child B-Not_AE_Candidate
- I-Not_AE_Candidate
Pugh I-Not_AE_Candidate
class I-Not_AE_Candidate
B I-Not_AE_Candidate
) O
. O

INLYTA O
has O
not O
been O
studied O
in O
patients O
with O
severe O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
( O
Child B-Not_AE_Candidate
- I-Not_AE_Candidate
Pugh I-Not_AE_Candidate
class I-Not_AE_Candidate
C I-Not_AE_Candidate
) O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
, O
and O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

5.13 O
Pregnancy O
INLYTA O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
based O
on O
its O
mechanism O
of O
action O
. O

There O
are O
no O
adequate O
and O
well-controlled O
studies O
in O
pregnant B-Not_AE_Candidate
women O
using O
INLYTA O
. O

In O
developmental B-NonOSE_AE
toxicity I-NonOSE_AE
studies O
in O
mice O
, O
axitinib O
was O
teratogenic B-NonOSE_AE
, O
embryotoxic B-NonOSE_AE
and O
fetotoxic B-NonOSE_AE
at O
maternal O
exposures O
that O
were O
lower O
than O
human O
exposures O
at O
the O
recommended O
clinical O
dose O
. O

Women O
of O
childbearing O
potential O
should O
be O
advised O
to O
avoid O
becoming O
pregnant B-NonOSE_AE
while O
receiving O
INLYTA O
. O

If O
this O
drug O
is O
used O
during O
pregnancy B-Not_AE_Candidate
, O
or O
if O
a O
patient O
becomes O
pregnant B-NonOSE_AE
while O
receiving O
this O
drug O
, O
the O
patient O
should O
be O
apprised O
of O
the O
potential O
hazard B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

